Skip to main content
Year archive

CLINUVEL PHARMACEUTICALS LIMITED — 2020 filings

All 69 regulatory filings released by CLINUVEL PHARMACEUTICALS LIMITED (CUV) in 2020, sourced directly from the official regulator.

69 Filings
2020 Period
2020 filings (69)
Filing Released Lang
Appendix 3G 16 pages 315.2KB
Share Issue/Capital Change
2020-12-23 English
Change in Substantial Holding 4 pages 219.4KB
Major Shareholding Notification
2020-12-21 English
CLINUVEL Newsletter 8 pages 278.9KB
Management Reports
2020-12-21 English
SCENESSE DNA Repair Study Approved to Commence 3 pages 254.9KB
Regulatory Filings
2020-11-29 English
Presentation Jefferies Virtual London Healthcare Conference 16 pages 901.8KB
Investor Presentation
2020-11-19 English
Chair Letter 3 pages 141.3KB
AGM Information
2020-11-18 English
Results of Meeting 2 pages 147.8KB
Declaration of Voting Results & Voting Rights Announcements
2020-11-11 English
Managing Directors AGM Presentation 25 pages 1.1MB
AGM Information
2020-11-10 English
Chair Address 3 pages 153.6KB
AGM Information
2020-11-10 English
Appendix 4C - quarterly 9 pages 426.7KB
Interim / Quarterly Report
2020-10-28 English
CLINUVEL Strategic Update - Extended 41 pages 12.5MB
Investor Presentation
2020-10-28 English
CLINUVEL Strategic Update - Executive Summary 19 pages 7.4MB
Investor Presentation
2020-10-28 English
afamelanotide for Acute Stroke Patients 4 pages 315.3KB
Regulatory Filings
2020-10-27 English
Media Release - CLINUVEL to Trial Innovative Drug in Stroke 3 pages 268.0KB
Regulatory Filings
2020-10-27 English
Australian TGA approves SCENESSE 3 pages 200.6KB
Regulatory Filings
2020-10-26 English
Media Release - TGA approves SCENESSE 3 pages 189.7KB
Regulatory Filings
2020-10-26 English
SCENESSE DNA Repair Update 3 pages 219.7KB
Regulatory Filings
2020-10-25 English
Trading Halt 2 pages 193.7KB
Regulatory Filings
2020-10-25 English
Further Research Coverage Initiated on CLINUVEL 2 pages 168.9KB
Regulatory Filings
2020-10-12 English
Notice of Annual General Meeting/Proxy Form 11 pages 538.4KB
AGM Information
2020-10-08 English
Annual Report to shareholders 84 pages 7.4MB
Annual Report
2020-10-08 English
Appendix 4G and Corporate Governance Statement 18 pages 515.7KB
Governance Information
2020-10-08 English
Presentation - Value in the Vines Investor Conference 11 pages 406.5KB
Investor Presentation
2020-10-08 English
CLINUVEL Confirms AGM Date 2 pages 133.0KB
AGM Information
2020-09-22 English
CLINUVEL Newsletter 8 pages 396.6KB
Annual Report
2020-09-22 English
Change of Director's Interest Notice 2 pages 222.8KB
Director's Dealing
2020-09-15 English
First patient dosed in SCENESSE DNA Repair Program 3 pages 231.3KB
Regulatory Filings
2020-09-14 English
Media Release - First patient dosed in SCENESSE DNA Repair 3 pages 275.9KB
Regulatory Filings
2020-09-14 English
SCENESSE in DNA Repair 5 pages 656.3KB
Regulatory Filings
2020-09-09 English
CLINUVEL progresses innovative DNA Repair Program 4 pages 640.0KB
Regulatory Filings
2020-09-09 English
Proposed issue of Securities - CUV 5 pages 28.7KB
Capital/Financing Update
2020-08-31 English
Change of Director's Interest Notice 2 pages 233.4KB
Director's Dealing
2020-08-31 English
Opening of VALLAURIX R&D Facilities in Singapore 3 pages 508.1KB
Regulatory Filings
2020-08-30 English
Media Release - CLINUVEL opens R&D centre in Singapore 3 pages 436.2KB
Regulatory Filings
2020-08-30 English
Appendix 4E and Preliminary Financial Report 55 pages 1.5MB
Annual Report
2020-08-26 English
CLINUVEL Full Year Results 3 pages 166.4KB
Annual Report
2020-08-26 English
CLINUVEL Declares Full Year Dividend 2 pages 171.3KB
Notice of Dividend Amount
2020-08-26 English
Dividend/Distribution - CUV 4 pages 24.9KB
Notice of Dividend Amount
2020-08-26 English
Corporate Presentation - 2020 Full Year Results 11 pages 429.7KB
Annual Report
2020-08-26 English
Appendix 4C - quarterly 9 pages 392.7KB
Interim / Quarterly Report
2020-07-30 English
CLINUVEL Corporate Update 12 pages 875.0KB
Interim / Quarterly Report
2020-07-30 English
CLINUVEL Newsletter 10 pages 285.2KB
Management Reports
2020-07-21 English
PRENUMBRA - New Liquid afamelanotide Presentation 4 pages 315.4KB
Capital/Financing Update
2020-07-12 English
Media Release - Second afamelanotide Formulation 3 pages 434.0KB
Regulatory Filings
2020-07-12 English
Lapse and Forfeit of Unlisted Conditional Performance Rights 2 pages 139.9KB
Share Issue/Capital Change
2020-07-07 English
Presentation Jefferies Global Healthcare Conference 14 pages 774.4KB
Investor Presentation
2020-06-04 English
Presentation UBS Global Healthcare Conference 15 pages 825.6KB
Investor Presentation
2020-05-19 English
CLINUVEL Newsletter 10 pages 1.0MB
Management Reports
2020-05-18 English
Chair Letter to Shareholders 4 pages 151.3KB
Management Reports
2020-05-07 English
FDA Type C Meeting for SCENESSE in Vitiligo 3 pages 567.2KB
Regulatory Filings
2020-04-30 English
Appendix 4C - quarterly 9 pages 344.3KB
Interim / Quarterly Report
2020-04-27 English
CLINUVEL starts SCENESSE supply into China 4 pages 228.2KB
Regulatory Filings
2020-04-22 English
Media Release - SCENESSE to be prescribed in China 3 pages 252.9KB
Capital/Financing Update
2020-04-22 English
First US Patients to be treated with SCENESSE 3 pages 358.2KB
Regulatory Filings
2020-04-15 English
Media Release - Innovative drug launched in US 3 pages 301.8KB
Regulatory Filings
2020-04-15 English
US Distribution Update 18 pages 892.0KB
Investor Presentation
2020-03-22 English
CLINUVEL to Launch SCENESSE in USA in April 2 pages 161.9KB
Capital/Financing Update
2020-03-22 English
CLINUVEL Newsletter 8 pages 594.7KB
Management Reports
2020-03-18 English
Chair Letter to Shareholders 5 pages 185.1KB
Management Reports
2020-03-11 English
FDA Meeting Confirmed to Advance SCENESSE in Vitiligo 3 pages 192.5KB
Regulatory Filings
2020-03-02 English
Supply of SCENESSE Unaffected by Coronavirus 2 pages 152.0KB
Regulatory Filings
2020-03-01 English
Corporate Presentation Half Year Results 18 pages 1.9MB
Interim / Quarterly Report
2020-02-26 English
Appendix 4D Half Yearly Report 20 pages 582.9KB
Interim / Quarterly Report
2020-02-25 English
Appendix 3B and Appendix 3Y Withdrawn 4 pages 270.8KB
Director's Dealing
2020-02-24 English
CLINUVEL to expand its Singapore laboratories 2 pages 185.6KB
Regulatory Filings
2020-02-23 English
Request for FDA Guidance Meeting SCENESSE in Vitiligo 3 pages 168.7KB
Regulatory Filings
2020-02-09 English
Australian TGA Commences SCENESSE Review 3 pages 161.6KB
Regulatory Filings
2020-02-02 English
Appendix 4C - quarterly 8 pages 253.3KB
Interim / Quarterly Report
2020-01-30 English
CLINUVEL Newsletter 7 pages 556.1KB
Management Reports
2020-01-15 English